Evotec Se · XETR:EVT
Evotec — BioCapital Europe 2019
27 slides from Evotec's conference presentation, Mar 14, 2019
Slide 1: Evotec: Partnered Drug Discovery and Development
Evotec Partnered Drug Discovery and Development Evotec AG, Company Presentation, BioCapital Europe 2019, Amsterdam, 14 March 2019
Slide 2: Forward-looking statement
Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking sta
Slide 3: Agenda
Agenda Overview Partnered drug discovery & development Financials & Outlook PAGE 2
Slide 4: Leading external drug discovery & development
Leading external drug discovery & development Company snapshot 100+ € 350 m+ € 80 m+ Co-owned pipeline Revenues1) Adjusted Group EBITDA1) programmes with significant milestone & royalty potential 25+ 2,500+ 200+ Years track record Top-class employees Long-term partnerships PAGE 3 1) in 2018
Slide 5: Medicine of the future will see radical change
Medicine of the future will see radical change Technologies & mega trends Next gen sequencing More precise & early diagnostics iPSC & CRISPR gene editing Patient-centric medicine RNAi technologies, CAR-T Digital health Checkpoint inhibitors Predictive & preventive medicine & Partners Artificial inte
Slide 6: From fixed to variable costs
From fixed to variable costs R&D outsourcing in € bn ~30-36 ~85-90 ~10 100% 90% 80% 55 5 (~60%) (~50%) 70% ~7 60% (~70%) ~25 Capital (~90%) ∑ 50% Elasticity € ~150 bn 40% 30% 35 5 20% (~50%) (~50%) ~3 10% (~30%) ~3 (10%) 0% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Discovery Pre-clinical/IND Manuf
Slide 7: Building a co-owned portfolio in partnerships
Building a co-owned portfolio in partnerships Unique strategy and business approach – Action Plan 2022 Own R&D Co-Owned Pipeline Action Plan 2022 Fee for Service PAGE 6
Slide 8: R&D solutions up to IND and CMC manufacturing
R&D solutions up to IND and CMC manufacturing Our core competencies Pre- Hit- Lead Target ID/ clinical identi- optimi- Phase I Phase II Phase III Approval Market validation Tox fication sation testing PAGE 7
Slide 9: > 2,500 x unique expertise
> 2,500 x unique expertise Global centres of excellence Abingdon, Alderley Park ~650 employees Hamburg, Göttingen, Munich ~550 employees Verona, Basel Princeton, Watertown, Branford Toulouse, Lyon ~650 employees ~150 employees ~550 employees PAGE 8
Slide 10: Agenda
Agenda Overview Partnered drug discovery & development Financials & Outlook PAGE 9
Slide 11: ONE fully integrated platform
ONE fully integrated platform EVT Execute & EVT Innovate IP stays with IP stays customers with Evotec PAGE 10 IP = Intellectual Property
Slide 12: Improving quality and accelerating R&D
Improving quality and accelerating R&D EVT Execute – Selected performance indicators 1,000,000+ >50 >10 Compounds in highly IND – Pre-clinical & Technology acquisitions1) selective library clinical candidates delivered (INDiGO)1) >80% >1.8 >25% Repeat business Years average Faster delivery of data c
Slide 13: Strong and well-balanced global customer mix
Strong and well-balanced global customer mix Who are our partners? in % RoW Foundations 10 5 Mid-sized Pharma 15 Biotech 40 Customer Revenue 50 Europe USA 45 type1) by region1) 35 Top 20 Pharma PAGE 12 1) Third-party revenues only
Slide 14: Strong portfolio of highest quality partners
Strong portfolio of highest quality partners EVT Execute alliances – Examples Partnership focused Partnership focused Partnership covering Partnership focused Partnership focused Partnership focused Partnership focused on Huntington on various broad range of on DMPK services on infectious on various
Slide 15: Building a co-owned pipeline
Building a co-owned pipeline EVT Innovate – Selected performance indicators 7 >€ 1,000 bn >100 Disease areas of Unmet markets Co-owned pipe- core expertise1) addressed line programmes 10 >10 100% Clinical Co- Unpartnered large First-in-class and best-in- owned assets R&D initiatives class approaches
Slide 16: Creating massive upside with limited cost & risk
Creating massive upside with limited cost & risk Example for co-owned deal structures Performance-based components (Illustrative) PAGE 15
Slide 17: > 100 projects in fully invested pipeline
> 100 projects in fully invested pipeline Partnership portfolio PAGE 16 1) Not disclosed Note: Several projects have fallen back to Evotec, where Evotec does not intend to run further clinical trials unpartnered, e.g. EVT302, EVT101, …
Slide 18: Re-defining the drug discovery paradigm
Re-defining the drug discovery paradigm Game-changing platforms for better translation Translational Holistic Superior Models Profiles Knowledge iPSC PanOmics AI & ML platform platform platform1) PAGE 17 1) Artificial Intelligence & Machine learning
Slide 19: Patient-derived assays as new gold standard
Patient-derived assays as new gold standard World-leading iPSC processes and network “IPS cells can become a power- Disease-specific drugs ful tool to develop new drugs to cure Screening intractable dis- Patient eases because they can be made from patients’ somatic cells.” Disease Patient- in a dish
Slide 20: BRIDGEs over the Valley of death
BRIDGEs over the “Valley of death“ The funding gap Basic Applied Technology Development Product Commercialisation Market Entry Research Research and Demonstration and Market Development and Market Volume Funding Level Public Market Project Governments Finance Funding Gap Banks/Credit Lines Sponsored
Slide 21: Long-term optionality with efficient translation
Long-term optionality with efficient translation BRIDGEs & Equity participations – Examples Equity participation Equity participation Equity participation Equity participation Equity participation Consortium membership Artificial Intelligence for Facioscapulohumeral Metabolic disorders Fibrosis part
Slide 22: Agenda
Agenda Overview Partnered drug discovery & development Financials & Outlook PAGE 21
Slide 23: Strong performance continues
Strong performance continues Financial history 2015-2019 (e) – Selected performance indicators Total Group revenues (in € m) R&D expenses (in € m) 257.3 18.3 18.1 17.6 164.5 127.7 2015 2016 2017 2018(e) 2019(e) 2015 2016 2017 2018(e) 2019(e) Adjusted Group EBITDA (in € m) Gross margin1) (in %) 35.6
Slide 24: Strong team and shareholders for innovation
Strong team and shareholders for innovation Management & shareholder structure ̴ 9% Roland >3% AGI1) >3% DWS2) Oetker/ROI Management Board Supervisory Board >3% Goldman Sachs Werner Lanthaler (CEO) Wolfgang Plischke Long-time experience in Pharma Ex-Bayer >3% and biotech Bernd Hirsch BlackRock
Slide 25: Strong outlook for 2019
Strong outlook for 2019 Expected key milestones 2019 Continued strong growth and new integrated service alliances New co-owned partnerships from own R&D New clinical initiations and important progress of co-owned pipeline Important milestones from existing alliances PAGE 24
Slide 26: PAGE
e, evotec #RESEARCHNEVERSTOFS
Slide 27: Your contact: Enno Spillner
Your contact: Enno Spillner Chief Financial Officer +49.(0).40.560 81-238 +49.(0).40.560 81-333 Fax enno.spillner@evotec.com